Li Yan, MD/PhD, Chief Medical Officer of Brii Biosciences, is a seasoned drug developer. He held executive positions at GSK, Merck, and Johnson & Johnson, most recently, VP and Oncology Head Unit Physician of GSK. He contributed to the development and approval of numerous medicines including Keytruda™ in China. His passion is to bring innovative medicines to transform patients’ lives, especially those in underprivileged communities. He firmly believes in the power of global collaboration. Li is a graduate of Peking University Medical College where he is an adjunct professor. He is an alumnus of Harvard Business School Enterprise Leadership program.